

RED CELLS, IRON, AND ERYTHROPOIESIS

Smad1/5 is required for erythropoietin-mediated suppression of hepcidin in mice

Chia-Yu Wang,^{1,2} Amanda B. Core,^{1,2} Susanna Canali,^{1,2} Kimberly B. Zumbrennen-Bullough,^{1,2} Sinan Ozer,³ Lieve Umans,⁴ An Zwijsen,⁴ and Jodie L. Babitt^{1,2}

¹Program in Anemia Signaling Research, Division of Nephrology, and ²Program in Membrane Biology, Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; ³Center for Engineering in Medicine, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Shriners Hospitals for Children, Boston, MA; and ⁴Laboratory of Developmental Signaling, VIB Center for the Biology of Disease, KU Leuven, Leuven, Belgium

Key Points

- The presence of Smad1 or Smad5 in hepatocytes is sufficient to maintain iron homeostasis, whereas deficiency of both induces iron overload.
- Erythropoietin and erythroferrone fail to suppress hepcidin in mice with a conditional ablation of *Smad1* and *Smad5* in hepatocytes.

Anemia suppresses liver hepcidin expression to supply adequate iron for erythropoiesis. Erythroferrone mediates hepcidin suppression by anemia, but its mechanism of action remains uncertain. The bone morphogenetic protein (BMP)–SMAD signaling pathway has a central role in hepcidin transcriptional regulation. Here, we explored the contribution of individual receptor-activated SMADs in hepcidin regulation and their involvement in erythroferrone suppression of hepcidin. In Hep3B cells, *SMAD5* or *SMAD1* but not *SMAD8*, knockdown inhibited hepcidin (*HAMP*) messenger RNA (mRNA) expression. Hepatocyte-specific double-knockout *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice exhibited ~90% transferrin saturation and massive liver iron overload, whereas *Smad1^{fl/fl};Smad5^{fl/wt};Cre⁺* mice or *Smad1^{fl/wt};Smad5^{fl/fl};Cre⁺* female mice with 1 functional *Smad5* or *Smad1* allele had modestly increased serum and liver iron, and single-knockout *Smad5^{fl/fl};Cre⁺* or *Smad1^{fl/fl};Cre⁺* mice had minimal to no iron loading, suggesting a gene dosage effect. *Hamp* mRNA was reduced in all *Cre⁺* mouse livers at 12 days and in all *Cre⁺* primary hepatocytes. However, only double-knockout mice continued to exhibit low liver *Hamp* at 8 weeks and failed to induce *Hamp* in response to *Bmp6* in primary hepatocyte cultures.

Epoetin alfa (EPO) robustly induced bone marrow erythroferrone (*Fam132b*) mRNA in control and *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice but suppressed hepcidin only in control mice. Likewise, erythroferrone failed to decrease *Hamp* mRNA in *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* primary hepatocytes and *SMAD1/SMAD5* knockdown Hep3B cells. EPO and erythroferrone reduced liver Smad1/5 phosphorylation in parallel with *Hamp* mRNA in control mice and Hep3B cells. Thus, *Smad1* and *Smad5* have overlapping functions to govern hepcidin transcription. Moreover, erythropoietin and erythroferrone target Smad1/5 signaling and require Smad1/5 to suppress hepcidin expression. (*Blood*. 2017;130(1):73-83)

Introduction

Iron is an essential nutrient that participates in numerous enzymatic reactions and biological functions; however, too much iron can be toxic because of free-radical generation.¹ Abnormalities in systemic iron homeostasis affect nearly 1 billion people worldwide, leading to diseases such as anemia and hemochromatosis.^{2,3} Hepcidin is a peptide hormone secreted by the liver that plays a central role in regulating systemic iron balance by promoting degradation of the iron exporter ferroportin to inhibit dietary iron absorption and iron recycling from body stores.⁴ Hepcidin expression is induced by iron as a negative feedback mechanism to maintain steady-state iron levels^{5,6} and by inflammation to limit iron availability to pathogenic microorganisms.^{7,8} Conversely, hepcidin expression is inhibited by anemia and other stimulators of erythropoietic drive to increase the iron supply for erythropoiesis.⁹

At the molecular level, the bone morphogenetic protein (BMP)–SMAD signaling pathway is a major transcriptional regulator of

hepcidin. Not only is BMP-SMAD signaling central to hepcidin regulation by iron,^{10,11} but it also intersects with most other known hepcidin regulators.¹² One of the least well-understood pathways is how hepcidin expression is suppressed by erythropoietic drive. Erythropoietic suppression of hepcidin is dependent on an intact bone marrow and occurs indirectly through secreted factor(s) produced by proliferating red blood cell precursors.¹³ Recently, erythroferrone was demonstrated to be one such mediator of hepcidin suppression by erythropoietic drive.¹⁴ How erythroferrone suppresses hepcidin production and whether this pathway intersects with the BMP-SMAD signaling pathway remain uncertain.

BMPs act by binding to a complex of type I and type II serine/threonine kinase receptors to induce the phosphorylation of receptor-activated SMAD transcription factors (R-SMADs), which translocate to the nucleus to modulate gene expression after complexing with

Submitted 23 December 2016; accepted 18 April 2017. Prepublished online as *Blood* First Edition paper, 24 April 2017; DOI 10.1182/blood-2016-12-759423.

The online version of this article contains a data supplement.

There is an Inside *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2017 by The American Society of Hematology

SMAD4.¹⁵ Genetic mouse models have yielded important insights into the specific components of the BMP signaling pathway that control hepcidin production. These data suggest a model where the ligands BMP6 and BMP2 are produced in liver endothelial cells and have paracrine actions on BMP receptors and the coreceptor hemojuvelin in hepatocytes to regulate hepcidin transcription. Indeed, global or endothelial knockout of *Bmp6*,^{16,17} endothelial knockout of *Bmp2*,¹⁸ and global or hepatocyte knockout of *Hfe2* (encoding hemojuvelin)^{10,19} in mice each lead to hepcidin deficiency and iron overload. Hepatocyte knockout of the BMP type I receptors *Acvr1* or *Bmpr1a* also lead to hepcidin deficiency and iron overload, suggesting that both type I receptors are essential for hepcidin regulation.²⁰ For type II receptors, hepcidin expression and iron homeostasis are only impaired in mice that lack both *Acvr2a* and *Bmpr2* in hepatocytes, suggesting that these type II receptors have redundant functions in hepcidin regulation.²¹

Although the contributions of specific BMP ligands and receptors have been well established, little is known about the relative contribution of R-SMADs in hepcidin regulation and iron homeostasis. Three R-SMADs are phosphorylated in response to BMP signals: SMAD1, SMAD5, and SMAD8 (also known as SMAD9). Liver SMAD1/5/8 phosphorylation is induced by iron in parallel with hepcidin,²² and SMAD signaling is critical to BMP regulation of hepcidin expression because specific SMAD binding elements on the hepcidin promoter are required for hepcidin induction by BMPs.²³ Moreover, hepatocyte knockout of common mediator *Smad4* leads to hepcidin deficiency and iron overload.²⁴ Although R-SMADs have been shown to have redundant, dose-dependent functions in many biological contexts,²⁵⁻²⁷ they do not always have overlapping functions. For example, in zebrafish embryos, *Smad1* knockdown impairs myelopoiesis but enhances erythropoiesis, whereas *Smad5* knockdown causes erythropoiesis failure but normal macrophage numbers.²⁸ Additionally, transcript profiling shows a large set of genes that are regulated independently by *Smad1* and *Smad5*.²⁸ Global *Smad1* or *Smad5* knockout mice are embryonic lethal, but for different reasons, whereas *Smad8* knockout mice are viable.^{25,29-33} Although some differences can be explained by when, where, and to what extent R-SMADs are expressed, R-SMADs may also bind to different elements and transcriptional coactivators.³³⁻³⁹

Here, we used *in vitro* studies and conditional knockout mice to determine the relative contribution of R-SMADs to hepcidin regulation and iron homeostasis. We also took advantage of these mouse models to investigate whether the suppression of hepcidin by erythropoietic drive involves the BMP-SMAD pathway.

Methods

Cell culture and transfections

Human hepatoma Hep3B cells were cultured as previously described¹⁰ and reverse transfected with 20-nM small interfering RNA (siRNA) targeting *SMAD1*, *SMAD5*, *SMAD8*, or Control siRNA (Dharmacon) using DharmaFECT 4 (Dharmacon) for 48 hours. Primary hepatocytes were isolated and cultured as described in the supplemental Methods (available on the Blood Web site). Where indicated, cells were serum starved overnight with 1% fetal bovine serum and stimulated with Bmp6 (R&D Systems) at 5 ng/mL for 6 hours or treated with conditioned medium containing 50% (volume-to-volume ratio) cell supernatant from control HEK293T cells or HEK293T cells overexpressing erythropoietin (Erfe-CM)¹⁴ for 15 or 6 hours.

Animals

Mice harboring LoxP-flanked alleles of both *Smad1* and *Smad5* (*Smad1^{fl/fl}*; *Smad5^{fl/fl}*) on a mixed C57BL/6J;129S5/SvEvBrd background²⁶ were crossed

with mice expressing a Cre transgene under the control of a hepatocyte-specific albumin promoter⁴⁰ on a C57BL/6J background (Jackson Laboratory). *Smad1^{fl/fl}*; *Smad5^{fl/fl}*; *Cre⁺* offspring were either backcrossed with *Smad1^{fl/fl}*; *Smad5^{fl/fl}* mice to generate *Smad1^{fl/fl}*; *Smad5^{fl/fl}*; *Cre⁺*, *Smad1^{fl/wt}*; *Smad5^{fl/fl}*; *Cre⁺*, and *Smad1^{fl/fl}*; *Smad5^{fl/wt}*; *Cre⁺* mice or intercrossed with *Smad1^{fl/wt}*; *Smad5^{fl/wt}*; *Cre⁻* to generate single-knockout *Smad5^{fl/fl}*; *Cre⁺* and *Smad1^{fl/fl}*; *Cre⁺* mice. *Cre⁺* mice were compared with littermate *Cre⁻* controls throughout the study. Mice were weaned at 3 weeks, maintained on a standard diet (Prolab RMH 3000; LabDiet) containing 380 ppm iron, and genotyped as previously described.^{26,41} Where indicated, mice were treated with a low-iron (2-6 ppm) diet (TD.80396; Harlan Laboratories), epoetin alfa (EPO; 200 U per mouse; Amgen), or neutralizing BMP6 (5 mg/kg of body weight; MAB507; R&D Systems)¹⁶ and BMP2/4 antibodies (10 mg/kg of body weight; MAB3552; R&D Systems; supplemental Figure 1). Animal protocols were approved by the Institutional Animal Care and Use Committee at Massachusetts General Hospital.

RNA extraction and quantitative reverse-transcriptase PCR

Total RNA was isolated using Qiashredder and RNeasy Mini Kit (Qiagen). First-strand complementary DNA (cDNA) was synthesized from 1 µg of RNA using the High-Capacity RNA-to-cDNA Kit (Applied Biosystems). Polymerase chain reactions (PCRs) were performed using the PowerUp SYBR Green Master Mix on the QuantStudio3 real-time PCR system (Applied Biosystems) using primers listed in supplemental Table 1. Transcript levels were normalized to *Rpl19* as an internal control. Transcript copy numbers of *SMAD1* and *SMAD5* were determined using Taqman Universal Master Mix, TaqMan primers and probes that were selected to target all known mRNA variants (Applied Biosystems), and standard curves that were generated from the plasmids listed in supplemental Table 2.

Iron analysis

Serum iron and unsaturated iron binding capacity were measured by colorimetric assay (Pointe Scientific) to calculate transferrin saturation according to manufacturer's instructions. Tissue nonheme iron concentrations (in micrograms per gram wet weight) were determined as described previously.⁴²

Immunoblot

Liver and cell lysates were prepared and immunoblots performed as described in the supplemental data using rabbit anti-Smad1 (1:1000; 9743S; Cell Signaling), rabbit anti-Smad5 (1:1000; ab40771; Abcam), rabbit anti-phosphorylated Smad5 (pSmad5; 1:500; ab92698; Abcam [hereafter called pSmad1/5 antibody because of crossreactivity with pSmad1]), or mouse anti-actin (1:20 000; MAB1501; Millipore) antibodies. Antibodies had been verified previously⁴³ or were verified as shown in supplemental Figure 2. Chemiluminescence quantitation of scanned films was performed using ImageJ 1.46v.

Statistics

All data are shown as mean ± standard error of the mean. Means were compared by Student unpaired *t* test, paired *t* test, or 1-way analysis of variance with Dunnett's post hoc test using Prism 7 (GraphPad). *P* < .05 was considered significant.

Results

SMAD5 has a dominant role and SMAD1 a contributory role in stimulating hepcidin in Hep3B cells

To define the relative contribution of BMP R-SMADs in hepcidin transcription, we first used siRNA to knockdown *SMAD1*, *SMAD5*, or *SMAD8* and measured *HAMP* mRNA levels in human hepatoma Hep3B cells. Knockdown efficiency and specificity for each siRNA were verified (supplemental Figure 3). Under basal conditions, *SMAD5* siRNA, but not *SMAD1* or *SMAD8* siRNA, inhibited *HAMP* mRNA expression (Figure 1 left). *SMAD5* knockdown also robustly inhibited




Figure 1. SMAD5 has a dominant role and SMAD1 a contributory role in the regulation of hepcidin in Hep3B cells. Hep3B cells were transfected with negative control (CTRL), *SMAD1*, *SMAD5*, or *SMAD8* siRNA (20 nM), serum starved with 1% fetal bovine serum overnight, and incubated in the absence or presence of 5 ng/ml of BMP6 for 6 hours. Relative *HAMP* mRNA levels were determined using quantitative reverse-transcriptase PCR. Transcripts were normalized to an internal control *RPL19*, and the average of CTRL without BMP6 stimulation was set to 1. Values represent mean \pm standard error of the mean. * $P < .05$; *** $P < .001$ relative to the respective CTRL by 1-way analysis of variance with Dunnett's post hoc test ($n = 3$ -4 per group).

BMP6 stimulation of *HAMP* mRNA ($\sim 90\%$), whereas *SMAD1* knockdown had a modest inhibitory effect ($\sim 30\%$), and *SMAD8* knockdown had no significant effect (Figure 1 right). Given the dominant role of *SMAD5* and, to a lesser extent, *SMAD1* in regulating hepcidin expression in vitro, we therefore generated mice with a conditional knockout of *Smad5*, *Smad1*, or the combination of *Smad1* and *Smad5* in hepatocytes to determine their relative contributions to hepcidin expression in vivo.

Validation of mice with a hepatocyte-specific inactivation of *Smad5* and/or *Smad1*

Smad1^{fl/fl};Smad5^{fl/fl} mice²⁶ were crossed with mice expressing a hepatocyte-specific Cre transgene⁴⁰ to generate mice with hepatocyte-specific inactivation of *Smad5* (*Smad5^{fl/fl};Cre⁺*), *Smad1* (*Smad1^{fl/fl};Cre⁺*), or both (*Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺*). All mice were compared with littermate *Cre⁻* controls. We also generated hepatocyte-specific *Smad5* knockout mice with 1 functional allele of *Smad1* (*Smad1^{fl/wt};Smad5^{fl/fl};Cre⁺*) and hepatocyte-specific *Smad1* knockout mice with 1 functional allele of *Smad5* (*Smad1^{fl/fl};Smad5^{fl/wt};Cre⁺*) and their respective *Cre⁻* littermate controls to study the impact of ablating 3 of 4 *Smad1/5* alleles.

In the *Cre⁺* mice, excision of the *LoxP*-flanked region was confirmed by PCR of genomic DNA from total liver (which includes both hepatocytes and nonparenchymal cells; Figure 2A). Quantitative reverse-transcriptase PCR analysis demonstrated that *Smad5* and *Smad1* mRNA levels were 77% lower in total liver and $>95\%$ lower in isolated hepatocytes of double-knockout *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice compared with littermate controls (*Smad1^{fl/fl};Smad5^{fl/fl};Cre⁻*; Figure 2B-C). Similar reductions in *Smad5* and *Smad1* mRNA were seen in single-knockout *Smad5^{fl/fl};Cre⁺* and *Smad1^{fl/fl};Cre⁺* mice compared with respective *Cre⁻* littermate controls. No compensatory increases were seen in *Smad1* or *Smad5* mRNA in *Smad5^{fl/fl};Cre⁺* or *Smad1^{fl/fl};Cre⁺* mice, respectively. *Smad8* mRNA was unchanged in single-knockout mice but was reduced in double-knockout mice, consistent with previous findings that *Smad8* expression is positively

regulated by Bmp signaling,⁴⁴ which we confirmed in Hep3B cells (supplemental Figure 4). Western blot analysis of whole-liver lysate detected an immunoreactive band for both *Smad5* and *Smad1* at ~ 55 kDa in *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁻* mice but not in *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice (Figure 2D), thus confirming the loss of hepatic *Smad5* and *Smad1* protein expression. Liver lysates of *Smad5^{fl/fl};Cre⁺* and *Smad1^{fl/fl};Cre⁺* mice also showed the loss of *Smad5* and *Smad1* protein expression, respectively, without compensatory increases in the remaining *Smad* protein (Figure 2D). A similar band pattern was detected for both *Smad5* and *Smad1* in primary hepatocytes isolated from these animals (data not shown).

Hepatocyte ablation of both *Smad5* and *Smad1* is required for developing massive iron overload in mice

To examine the relative contributions of *Smad5* and *Smad1* in hepcidin regulation and iron homeostasis in vivo, we first examined iron status parameters in hepatocyte-specific single-knockout *Smad5^{fl/fl};Cre⁺* and *Smad1^{fl/fl};Cre⁺* mice at 8 weeks of age. Serum transferrin saturation was not affected in *Smad5^{fl/fl};Cre⁺* or *Smad1^{fl/fl};Cre⁺* mice of either sex (Figure 3A). Liver nonheme iron concentrations did not differ in *Smad5^{fl/fl};Cre⁺* or *Smad1^{fl/fl};Cre⁺* male mice; however, we observed a subtle increase in liver iron levels in *Smad1^{fl/fl};Cre⁺*, but not in *Smad5^{fl/fl};Cre⁺*, female mice (Figure 3B). Next, we examined iron parameters in mice with 1 remaining functional allele of *Smad1* (*Smad1^{fl/wt};Smad5^{fl/fl};Cre⁺*) or *Smad5* (*Smad1^{fl/wt};Smad5^{fl/wt};Cre⁺*) in hepatocytes. We found that *Smad1^{fl/wt};Smad5^{fl/fl};Cre⁺* female mice and *Smad1^{fl/wt};Smad5^{fl/wt};Cre⁺* male and female mice displayed mildly elevated levels of transferrin saturation and liver iron at 8 weeks. Finally, we examined hepatocyte-specific double-knockout *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice. Both male and female *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice had $\sim 90\%$ transferrin saturation and developed massive liver iron overload (Figure 3C-D) at 8 weeks of age.

Next, we measured hepatic *Hamp* mRNA expression in mice of each genotype. Interestingly, only double-knockout *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice displayed significantly reduced *Hamp* mRNA expression compared with littermate *Cre⁻* mice at 8 weeks of age (Figure 4A-B). Notably, hepcidin expression is induced by iron. *Hamp* mRNA levels may therefore be inappropriately low relative to iron levels in *Smad1^{fl/wt};Smad5^{fl/fl};Cre⁺* female mice and *Smad1^{fl/wt};Smad5^{fl/wt};Cre⁺* mice that exhibit some degree of iron loading. We therefore examined *Hamp* mRNA levels at an earlier age before mice were exposed to the high iron content of the standard rodent diet. Although mice are typically weaned at 3 weeks of age, they can start nibbling solid food as early as 2 weeks old. Therefore, we harvested mice at 12 days to minimize the effect of dietary iron. At 12 days, *Hamp* mRNA levels were significantly reduced in all *Cre⁺* mice (Figure 4C-D), when liver iron content was not yet increased (supplemental Figure 5).

We then tested the ability of primary hepatocytes from mice of each genotype to respond to Bmp6 stimulation. Consistent with total liver *Hamp* mRNA levels in 12-day-old mice, baseline *Hamp* mRNA levels were significantly reduced in primary hepatocytes of all *Cre⁺* genotypes (Figure 5A). In contrast to the findings in human Hep3B cells where *SMAD5* had a dominant role (Figure 1), *Smad1* seemed to have a greater role in baseline *Hamp* mRNA expression in mouse primary hepatocytes, because primary hepatocytes from *Smad1^{fl/fl};Cre⁺* and *Smad1^{fl/fl};Smad5^{fl/wt};Cre⁺* mice had greater reductions in baseline *Hamp* mRNA relative to littermate *Cre⁻* mice compared with *Smad5^{fl/fl};Cre⁺* and *Smad1^{fl/wt};Smad5^{fl/fl};Cre⁺* mice, respectively. The higher expression of *Smad1* relative to *Smad5* in mouse hepatocytes compared with the lower expression of *SMAD1* relative to *SMAD5* in human Hep3B cells (Figure 5B-C) may explain




Figure 2. Confirmation of hepatocyte *Smad1* and/or *Smad5* ablation in conditional knockout mice. (A) Schematic depictions of loxP-flanked (floxed) *Smad1* or *Smad5* allele and the allele after Cre recombinase-mediated excision. F and R indicate forward and reverse primers used for PCR genotyping (left). PCR analysis of genomic DNA extracted from total liver (containing both hepatocytes and nonparenchymal cells) of double-knockout *Smad1^{fl/fl}; Smad5^{fl/fl}; Cre⁻* mice and littermate *Cre⁻* controls at 8 weeks of age (right). (B-C) Relative *Smad5* (B) and *Smad1* (C) mRNA levels in the total liver ($n = 7-9$ per group; 8 weeks of age) and isolated hepatocytes ($n = 3-4$ per group; 6 weeks of age) of *Smad5^{fl/fl}; Cre⁺*, *Smad1^{fl/fl}; Cre⁺*, and *Smad1^{fl/fl}; Smad5^{fl/fl}; Cre⁺* mice compared with their respective littermate *Cre⁻* controls. Transcripts were normalized to *Rpl19*, and the average of the respective *Cre⁻* control mice was set to 1. Values represent mean \pm standard error of the mean. $***P < .001$ relative to the respective *Cre⁻* controls by Student *t* test. (D) Western blot analysis of Smad5 and Smad1 in the livers of *Smad5^{fl/fl}; Cre⁺*, *Smad1^{fl/fl}; Cre⁺*, and *Smad1^{fl/fl}; Smad5^{fl/fl}; Cre⁺* mice compared with their respective littermate *Cre⁻* controls at 8 weeks of age. Actin is used as a loading control.




Figure 3. Hepatocyte *Smad1* or *Smad5* single-knockout mice exhibit minimal to no iron loading, whereas knockout of 3 or 4 *Smad1/5* alleles causes progressive serum and liver iron overload. (A-B) Serum transferrin saturation (Tf sat) (A) and hepatic nonheme iron concentrations (B) of *Smad5^{fl/fl};Cre⁺* and *Smad1^{fl/fl};Cre⁺* mice ($n = 5-7$ per group) compared with their respective littermate *Cre⁻* controls. (C-D) Serum transferrin saturation (C) and hepatic nonheme iron concentrations (D) of *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺*, *Smad1^{fl/fl};Smad5^{wt/wt};Cre⁺*, and double-knockout *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice compared with their respective littermate *Cre⁻* controls ($n = 6-12$ per group). Values represent mean \pm standard error of the mean. * $P < .05$; ** $P < .01$; *** $P < .001$ relative to the respective *Cre⁻* controls by Student *t* test.

the apparent differences between the functional role of R-SMADs in hepcidin regulation in these systems.

Although basal levels were reduced, *Hamp* mRNA was induced by Bmp6 in all single-knockout and homozygous/heterozygous *Smad1^{fl/fl};Smad5^{fl/wt};Cre⁺* and *Smad1^{fl/wt};Smad5^{fl/fl};Cre⁺* strains (Figure 5D-G). *Hamp* mRNA levels were lower in Bmp6-stimulated *Cre⁺* hepatocytes compared with Bmp6-stimulated *Cre⁻* hepatocytes; however, the fold increases relative to unstimulated cells of the same genotype were generally similar. This preserved inducibility of *Hamp* may help account for the fact that *Hamp* mRNA levels in these mice seemed similar to littermate *Cre⁻* mice at 8 weeks of age after exposure to dietary iron, when Bmp signaling is induced. In contrast, *Hamp* mRNA levels failed to be induced by Bmp6 in double-knockout *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* primary hepatocytes (Figure 5H).

Smad1/5 is required for EPO and erythroferrone suppression of hepcidin in mice

To determine if erythropoietic suppression of hepcidin requires the BMP-SMAD pathway, we tested the effects of EPO injection in *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice. Consistent with previous findings,^{14,45} EPO similarly induced erythroferrone (*Fam132b*) mRNA in the bone marrow of *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice and littermate controls (Figure 6A). However, whereas EPO robustly reduced liver *Hamp*

mRNA expression in *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁻* mice, it did not suppress *Hamp* in *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice (Figure 6B). Similar results were seen for serum hepcidin (supplemental Figure 6). This suggests that EPO requires an intact SMAD1/5 signaling pathway to suppress hepcidin expression. EPO suppression of hepcidin was preserved in single-knockout *Smad5^{fl/fl};Cre⁺* and *Smad1^{fl/fl};Cre⁺* mice, suggesting that *Smad1* and *Smad5* function redundantly in EPO-mediated hepcidin suppression (supplemental Figure 7). Notably, liver *Smad1/5* phosphorylation was significantly decreased in EPO-treated *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁻* mice compared with phosphate-buffered saline-treated mice (Figure 6C), similar to results in 1 prior report.⁴⁵ A trend toward lower mRNA expression of the Bmp-Smad1/5 target *Id1* was also observed in response to EPO treatment, but it did not reach statistical significance ($P = .07$; Figure 6D). These data raise the possibility that EPO may have a functional role in suppressing *Smad* pathway activity in the liver.

Because EPO acts indirectly to suppress hepcidin and could involve multiple mechanisms, we isolated primary hepatocytes from *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice and littermate controls to examine more specifically whether erythroferrone suppression of hepcidin requires *Smad1/5*. Whereas treatment with conditioned medium from HEK293T cells overexpressing erythroferrone (Erfe-CM)¹⁴ or transfection with *Fam132b* cDNA significantly decreased *Hamp* and *Id1* mRNA levels in primary hepatocytes from *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁻* mice, neither *Hamp*




Figure 4. Liver *Hamp* mRNA is reduced at 12 days of age in mice lacking 2 to 4 *Smad1/5* alleles but is reduced at 8 weeks of age only in double-knockout mice. Relative expression of *Hamp* was measured in *Smad5^{fl/fl};Cre⁺*, *Smad1^{fl/fl};Cre⁺*, *Smad1^{fl/wt};Smad5^{fl/fl};Cre⁺*, *Smad1^{fl/fl};Smad5^{fl/wt};Cre⁺*, *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺*, and littermate control *Cre⁻* mouse livers at 8 weeks (A-B; n = 5-11 per group) or 12 days (C-D; n = 3-6 per group) of age. Transcript levels were normalized to *Rpl19*, and the average of the respective littermate *Cre⁻* control mice was set to 1. Values represent mean \pm standard error of the mean. * $P < .05$; ** $P < .01$; *** $P < .001$ relative to the respective *Cre⁻* controls by Student *t* test.

nor *Id1* mRNA was reduced in hepatocytes from *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice (Figure 6E-F; supplemental Figure 8A-C). To examine a more direct effect for erythropoietin on Smad1/5 phosphorylation, we treated Hep3B cells with Erfe-CM for 6 hours. Similar to mouse primary hepatocytes, Hep3B cells treated with Erfe-CM had reduced *HAMP* and *ID1* mRNA (Figure 6G-H), and notably, pSMAD1/5 was reduced $\sim 75\%$ (Figure 6I). *Fam132b* transfection likewise inhibited pSMAD1/5 protein, *HAMP*, and *ID1* mRNA in Hep3B cells (supplemental Figure 8D-F). Consistent with the primary hepatocyte data, siRNA-mediated knockdown of *SMAD1* and *SMAD5* blocked the ability of Erfe-CM to suppress *HAMP* mRNA in Hep3B cells (Figure 6J).

To rule out the possibility that basal hepcidin expression in *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice was not suppressible by EPO because it had already reached its nadir, we investigated whether hepcidin was suppressed by dietary iron deficiency in these mice. Liver *Hamp* mRNA, serum hepcidin, and liver iron levels were significantly lower in *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice fed a low-iron diet for 3 weeks after weaning compared with *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice fed a standard diet (Figure 7A-B left; supplemental Figure 9). Thus, hepcidin is further suppressible in *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice in some contexts. Interestingly, treatment with neutralizing BMP2/4 and BMP6 antibodies completely blocked the residual ability of iron in the standard

diet to increase *Hamp* mRNA in *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice, leading to more liver iron loading (Figure 7A-B right). This suggests that residual hepcidin induction by iron in the *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice is dependent on residual Bmp signaling.

Discussion

BMP-SMAD signaling is a central pathway in the regulation of hepcidin transcription.^{11,22} Although the contributions of specific BMP type I and type II receptors have been described,^{20,21} the role of individual R-SMADs remains to be elucidated. Our finding that hepatocyte-specific double-knockout *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* mice developed massive liver iron overload but single-knockout *Smad5^{fl/fl};Cre⁺* or *Smad1^{fl/fl};Cre⁺* mice had minimal to no iron loading at 8 weeks of age suggest that hepatocyte Smad1 and Smad5 have overlapping functions and work collaboratively to govern *Hamp* expression in the liver. The intermediate phenotype of *Smad1^{fl/wt};Smad5^{fl/fl};Cre⁺* and *Smad1^{fl/fl};Smad5^{fl/wt};Cre⁺* mice with 1 remaining functional *Smad1* or *Smad5* allele suggests a gene dosage effect. Although Smad1 and Smad5 have nonoverlapping functions in some contexts,²⁸ these




Figure 5. Hepcidin is induced by Bmp6 in primary hepatocytes from mice lacking 2 or 3 *Smad1/5* alleles but not in double-knockout mice. (A,D-H) Primary hepatocytes were isolated from 6-week-old male *Smad5^{fl/fl};Cre⁺*, *Smad1^{fl/fl};Cre⁺*, *Smad1^{fl/wt};Smad5^{fl/fl};Cre⁺*, *Smad1^{fl/fl};Smad5^{fl/wt};Cre⁺*, *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺*, and littermate *Cre⁻* control mice using 2-step collagenase digestion and cultured in collagen-coated plates. Cells were serum starved with 1% fetal bovine serum overnight before Bmp6 stimulation for 6 hours. Hepatocyte *Hamp* mRNA levels were determined at baseline (A; n = 4-5 per group) and after stimulation with Bmp6 (D-H; n = 3-5 per group) for each genotype. Transcript levels were normalized to *Fpl19*, and the average of the respective *Cre⁻* control mice without Bmp6 stimulation was set to 1. Values represent mean ± standard error of the mean. **P* < .05; ***P* < .01; ****P* < .001 relative to the respective *Cre⁻* controls (A) or unstimulated cells of the same genotype (D-H) by Student *t* test. Fold induction of *Hamp* mRNA in Bmp6-stimulated versus -nonstimulated cells for each genotype is indicated. (B-C) *Smad1* and *Smad5* mRNA copy numbers were determined using Taqman primers with probes targeting all known variants and quantitative reverse-transcriptase PCR in mouse primary hepatocytes (B) and human Hep3B cells (C; n = 4 per group). ns, not significant.

observations are consistent with many other studies where *Smad1* and *Smad5* were shown to have dose-dependent yet redundant functions, for example, in mouse embryo during early development,²⁵ in gonadal somatic cells for reproduction,²⁶ and in chondrocyte differentiation for bone formation.²⁷

The single-knockout *Smad5^{fl/fl};Cre⁺* or *Smad1^{fl/fl};Cre⁺* mice and mice with 1 remaining functional allele of *Smad1* or *Smad5* in hepatocytes (*Smad1^{fl/wt};Smad5^{fl/fl};Cre⁺* and *Smad1^{fl/fl};Smad5^{fl/wt};Cre⁺* mice, respectively) provide models to study the effects of more subtle defects in the BMP-SMAD signaling pathway. Liver *Hamp*




Figure 6. Smad1 and Smad5 are required for EPO and erythroferone suppression of hepcidin in mice. *Smad1^{fl/fl};Smad5^{fl/fl};Cre⁺* and littermate *Cre⁻* mice at 6 weeks of age were injected with phosphate-buffered saline (PBS) or EPO (200 U per mouse), and tissues were harvested after 15 hours to determine bone marrow *Fam132b* mRNA expression (A), liver *Hamp* mRNA (B), liver phosphorylated Smad1/5 protein (C), and liver *Id1* mRNA levels (D). Primary hepatocytes isolated from 6-week-old male




Figure 7. *Hamp* mRNA levels are suppressed in double-knockout mice treated with a low-iron diet. (A-B left) *Smad1^{fl/fl}; Smad5^{fl/fl}; Cre⁺* mice and littermate *Cre⁻* controls were fed a standard or low-iron diet (FeD) for 3 weeks upon weaning. (A-B right) *Smad1^{fl/fl}; Smad5^{fl/fl}; Cre⁺* mice were fed a low-iron diet for 2 weeks upon weaning and switched to standard diet for 1 week, coupled with 4 intraperitoneal injections of phosphate-buffered saline (PBS) or a mixture of neutralizing BMP2/4 (10 mg/kg of body weight) and BMP6 (5 mg/kg of body weight) antibodies in PBS administered every other day. Livers were harvested to measure *Hamp* mRNA levels (A) and nonheme iron concentrations (B; n = 3-8 per group). Values represent mean ± standard error of the mean. **P* < .05; ***P* < .01 relative to mice on a standard diet of the same genotype (left) or relative to PBS-treated mice (right) by Student *t* test.

expression was significantly reduced in all these models at 12 days of age as well as in isolated primary hepatocyte from 6-week-old animals, providing evidence that *Smad1* and *Smad5* have a role in maintaining basal *Hamp* mRNA levels. We attribute the lack of significant iron phenotype at 8 weeks of age in mice with 2 of 4 functional *Smad1* and *Smad5* alleles to the preserved inducibility of *Hamp* under Bmp6 and dietary iron exposure. Mice with 1 of 4 functional *Smad1* and *Smad5* alleles required higher iron levels to induce *Hamp* levels equivalent to those in *Cre⁻* littermate controls, thereby resulting in a mild iron overload phenotype. However, even the presence of 1 *Smad1* or *Smad5* allele was enough for hepcidin regulation to remain largely intact.

One apparent discrepancy between our in vitro and in vivo studies was that *SMAD5* had a dominant role in *HAMP* regulation by BMP6 in Hep3B cells, whereas *Smad1* had a slightly more prominent role in mice, because *Smad1^{fl/fl}; Smad5^{fl/wt}; Cre⁺* mice seemed to have lower hepcidin levels and a stronger iron phenotype than *Smad1^{fl/wt}; Smad5^{fl/fl}; Cre⁺* mice, at least in males. Notably, quantitative analysis revealed higher levels of *SMAD5* versus *SMAD1* in Hep3B cells compared with

lower levels of *Smad5* versus *Smad1* in mouse primary hepatocytes. These data suggest that both *Smad1* and *Smad5* can regulate *Hamp*, and we hypothesize that the difference between these models results from the relative expression of *Smad1* compared with *Smad5*. Given the differences between our models, we cannot exclude the possibility that *Smad8* may also have a role in hepcidin regulation and iron homeostasis in vivo, even though *SMAD8* knockdown did not inhibit *HAMP* expression in Hep3B cells. Previous work has indicated that *Smad8* has insignificant functions in embryo development and cartilage formation as a result of the redundancy with *Smad1* and *Smad5*.^{25,27} However, *Smad8* expression is increased by the activation of Bmp signaling and, at least in vitro, can function to suppress Bmp signaling by forming a heterodimer with *Smad1* and *Smad5* to inhibit their effects.^{44,46} Whether *Smad8* works to accelerate or antagonize Bmp signaling in the liver is currently under investigation.

The *Smad1^{fl/fl}; Smad5^{fl/fl}; Cre⁺* mice provide a model to study how the BMP R-SMAD pathway interacts with other hepcidin regulators for which the mechanism of action is less well understood. For example, we recently used these mice to demonstrate that hepcidin induction by endoplasmic reticulum stress requires *Smad1/5* signaling.⁴⁷ Here, we explored the role of *Smad1/5* in hepcidin suppression by erythropoietic drive. Several secreted proteins have been proposed to function as erythroid regulators of hepcidin, including growth differentiation factor 15,⁴⁸ twisted gastrulation BMP signaling modulator 1,⁴⁹ and erythropoietin.¹⁴ On the basis of recent studies, growth differentiation factor 15 and twisted gastrulation BMP signaling modulator 1 do not seem to be physiological suppressors of hepcidin.^{14,50-52} In contrast, erythropoietin seems essential, because *Fam132b*-knockout animals did not suppress hepcidin in response to acute erythropoiesis and had delayed recovery of hemoglobin after hemorrhage.¹⁴ Here, we found that EPO and erythropoietin did not further suppress hepcidin expression in hepatocytes lacking both *Smad1* and *Smad5*, suggesting that *Smad1/5* are required for EPO- and erythropoietin-mediated suppression of hepcidin. Previous work has reported that EPO suppression of hepcidin is not impaired in mice deficient for *Tfr2*, *Hfe2*, or *Bmp6*,^{14,45,53} nor in mice fed an iron-deficient diet for 3 weeks, all of which lead to suppressed *Smad* signaling in the liver. One possibility is that EPO and erythropoietin act further downstream in the *Smad* signaling cascade, or the residual *Smad* expression in these models may be enough to permit the hepcidin suppressive effects. Not only does a loss of *Smad1/5* block EPO and erythropoietin suppression of hepcidin, but EPO effects are also blunted when the *Smad1/5* pathway is highly induced, for example, in *Tmprss6*-knockout mice and mice fed a high-iron diet.⁴⁵ Similarly, in the context of thalassemia, where high erythropoietin/erythropoietin levels and iron overload coexist, *Hamp* mRNA was more suppressed in *Th3/+* mice maintained on a low-iron diet to achieve normal liver iron levels compared with mice on an iron-sufficient diet with iron overload.⁵⁴ Thus, *Smad1/5* signaling must be appropriately regulated for the maximal hepcidin suppressive effects of EPO and erythropoietin.

Interestingly, EPO injection in mice led to reduced liver pSmad1/5 expression and a strong trend toward lower expression of the

Figure 6 (continued) *Smad1^{fl/fl}; Smad5^{fl/fl}; Cre⁺* and littermate *Cre⁻* mice (E-F) and Hep3B cells (G-I) were treated with conditioned medium containing 50% (volume-to-volume ratio) cell supernatant from control HEK293T cells (Ctrl-CM) or Erfe-CM for 15 hours (E-F) or 6 hours (G-I), and the relative mRNA levels of *Hamp* (E,G), *Id1* (F,H), and pSMAD1/5 protein (I) were determined. (J) Hep3B cells were transfected with control siRNA or *SMAD1* and *SMAD5* siRNA for 48 hours before 6-hour Ctrl-CM or Erfe-CM treatment, and relative *HAMP* mRNA levels were determined. Transcript levels measured by quantitative reverse-transcriptase PCR were normalized to *Rpl19*. *Smad1/5* phosphorylation levels determined by immunoblot were normalized to total *Smad5*, and the average of PBS-treated *Cre⁻* control mice or Ctrl-CM-treated cells was set to 1. Representative immunoblots are shown. Values represent mean ± standard error of the mean (n = 4-5 mice per group in panel A; n = 10 mice per group in panels B-D; n = 4 per group in panels E-F; n = 3 per group in panels G-J). **P* < .05; ***P* < .01; ****P* < .001 relative to PBS-treated mice or Ctrl-CM-treated cells of the same genotype by Student *t* test. ns, not significant.

Smad1/5 target transcript *Id1*, suggesting that 1 mechanism by which erythroferone suppresses hepcidin may be by inhibiting Smad1/5 signaling. Although the initial report describing erythroferone failed to detect reduced liver pSmad5 in mice treated with EPO or phlebotomy, decreased *Id1* expression was seen after phlebotomy.¹⁴ Moreover, a recent study reported reduced liver pSmad5 and *Id1* after EPO injection in wild-type mice.⁴⁵ Additionally, several studies have described a failure to appropriately induce pSmad1/5 by iron overload in the context of ineffective erythropoiesis in thalassemia.^{52,55} However, a direct effect of erythroferone on Smad1/5 signaling has not previously been examined. Here, we demonstrated that treatment with erythroferone conditioned medium or transfection with *Fam132b* cDNA decreased SMAD1/5 phosphorylation and *Id1* expression in Hep3B cells in 6 hours, suggesting that erythroferone does have a functional role in suppressing SMAD1/5 signaling in hepatocytes. Although it has been proposed that *Tmprss6* mediates the liver pSmad1/5 reduction in response to EPO required for hepcidin suppression,⁴⁵ a recent correspondence reported that erythroferone still suppressed *Hamp* and *Id1* mRNA in *Tmprss6*^{-/-} primary hepatocytes,⁵⁶ suggesting a *Tmprss6*-independent effect. Future studies will be needed to understand the molecular mechanisms by which erythroferone suppresses Smad1/5 signaling and the full details of crosstalk between these pathways.

In contrast to the effects of EPO injection, a low-iron diet further suppressed hepcidin in double-knockout *Smad1*^{fl/fl}; *Smad5*^{fl/fl}; *Cre*⁺ mice. Interestingly, the residual ability of iron to increase hepcidin in the *Smad1*^{fl/fl}; *Smad5*^{fl/fl}; *Cre*⁺ mice on a standard diet compared with a low-iron diet was blocked by neutralizing BMP2/4 and BMP6 antibodies, suggesting that residual hepcidin induction by iron in these mice is dependent on residual Bmp signaling. Because Cre-mediated recombination is not 100% efficient, and because *Smad8* is still present, albeit at reduced levels, residual iron-mediated hepcidin expression in these mice may be governed by residual Smad1/5/8 signaling. Alternatively, a noncanonical pathway activated by BMPs could be involved.⁵⁷ However, this residual Bmp signaling in the *Smad1*^{fl/fl}; *Smad5*^{fl/fl}; *Cre*⁺ mice does not seem to be sufficient to mediate hepcidin suppression by erythropoietin.

In summary, our results demonstrate that Smad1 and Smad5 have redundant, dose-dependent roles in hepcidin regulation and iron homeostasis. Moreover, Smad1 and Smad5 are required for the

suppressive effects of erythropoietin and erythroferone on hepcidin to optimize iron availability for red blood cell production in the context of anemia. The *Smad1*^{fl/fl}; *Smad5*^{fl/fl}; *Cre*⁺ mice provide a new tool to understand how various signals are integrated to regulate hepcidin expression and govern systemic iron homeostasis.

Acknowledgments

The authors thank Elizabeth Robertson (University of Oxford, Oxford, United Kingdom) for kindly providing the *Smad1* floxed mice and Tomas Ganz and Elizabeth Nemeth (University of California Los Angeles, Los Angeles, CA) for graciously providing HEK293T cells overexpressing erythroferone and the conditioned media.

This work was supported by National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases grants RO1-DK087727 (J.L.B.) and T32 DK007540 (K.B.Z.-B. and A.B.C.) and a Howard Goodman Fellowship Award from the Massachusetts General Hospital (J.L.B.).

Authorship

Contribution: C.-Y.W. performed experiments, interpreted data, and wrote the paper; A.B.C. initiated the generation of the hepatocyte-specific Smad1/5 double-knockout mice and performed experiments; S.C. and S.O. assisted in mouse studies; K.B.Z.-B. performed knockdown studies; L.U. and A.Z. provided key reagents; and J.L.B. conceived and oversaw the study, interpreted data, and wrote the paper.

Conflict-of-interest disclosure: J.L.B. has ownership interest in Ferrumax Pharmaceuticals, which has licensed technology from the Massachusetts General Hospital based on work cited here and in prior publications. The remaining authors declare no competing financial interests.

Correspondence: Jodie L. Babitt, Massachusetts General Hospital, 185 Cambridge St, CPZN-8208, Boston, MA 02114; e-mail: babitt.jodie@mgh.harvard.edu.

References

- Chevion M. A site-specific mechanism for free radical induced biological damage: the essential role of redox-active transition metals. *Free Radic Biol Med*. 1988;5(1):27-37.
- Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med*. 2005;352(10):1011-1023.
- Pietrangelo A. Hereditary hemochromatosis. *Annu Rev Nutr*. 2006;26:251-270.
- Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science*. 2004;306(5704):2090-2093.
- Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. *J Biol Chem*. 2001;276(11):7811-7819.
- Anderson GJ, Frazer DM, Wilkins SJ, et al. Relationship between intestinal iron-transporter expression, hepatic hepcidin levels and the control of iron absorption. *Biochem Soc Trans*. 2002;30(4):724-726.
- Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. *Blood*. 2003;101(7):2461-2463.
- Wang CY, Babitt JL. Hepcidin regulation in the anemia of inflammation. *Curr Opin Hematol*. 2016;23(3):189-197.
- Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. *J Clin Invest*. 2002;110(7):1037-1044.
- Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. *Nat Genet*. 2006;38(5):531-539.
- Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. *J Clin Invest*. 2007;117(7):1933-1939.
- Core AB, Canali S, Babitt JL. Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis. *Front Pharmacol*. 2014;5:104.
- Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. *Blood*. 2006;108(12):3730-3735.
- Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferone as an erythroid regulator of iron metabolism. *Nat Genet*. 2014;46(7):678-684.
- Massagué J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. *EMBO J*. 2000;19(8):1745-1754.
- Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. *Nat Genet*. 2009;41(4):482-487.
- Canali S, Zumbrennen-Bullough KB, Core AB, et al. Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. *Blood*. 2017;129(4):405-414.
- Koch PS, Olsavsky V, Ulbrich F, et al. Angiocrine Bmp2 signaling in murine liver controls normal iron homeostasis. *Blood*. 2017;129(4):415-419.
- Chen W, Huang FW, de Renshaw TB, Andrews NC. Skeletal muscle hemojuvelin is dispensable

- for systemic iron homeostasis. *Blood*. 2011; 117(23):6319-6325.
20. Steinbicker AU, Bartnikas TB, Lohmeyer LK, et al. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. *Blood*. 2011;118(15):4224-4230.
 21. Mayeur C, Leyton PA, Kolodziej SA, Yu B, Bloch KD. BMP type II receptors have redundant roles in the regulation of hepatic hepcidin gene expression and iron metabolism. *Blood*. 2014; 124(13):2116-2123.
 22. Kautz L, Meynard D, Monnier A, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. *Blood*. 2008;112(4):1503-1509.
 23. Casanovas G, Mleczo-Sanecka K, Altamura S, Hentze MW, Muckenthaler MU. Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. *J Mol Med (Berl)*. 2009;87(5): 471-480.
 24. Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. *Cell Metab*. 2005;2(6): 399-409.
 25. Arnold SJ, Maretto S, Islam A, Bikoff EK, Robertson EJ. Dose-dependent Smad1, Smad5 and Smad8 signaling in the early mouse embryo. *Dev Biol*. 2006;296(1):104-118.
 26. Pangas SA, Li X, Umans L, et al. Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. *Mol Cell Biol*. 2008; 28(1):248-257.
 27. Retting KN, Song B, Yoon BS, Lyons KM. BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation. *Development*. 2009;136(7):1093-1104.
 28. McReynolds LJ, Gupta S, Figueroa ME, Mullins MC, Evans T. Smad1 and Smad5 differentially regulate embryonic hematopoiesis. *Blood*. 2007; 110(12):3881-3890.
 29. Chang H, Huylebroeck D, Verschueren K, Guo Q, Matzuk MM, Zwijsen A. Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. *Development*. 1999; 126(8):1631-1642.
 30. Yang X, Castilla LH, Xu X, et al. Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. *Development*. 1999;126(8): 1571-1580.
 31. Lechleider RJ, Ryan JL, Garrett L, et al. Targeted mutagenesis of Smad1 reveals an essential role in choriocallantoic fusion. *Dev Biol*. 2001;240(1): 157-167.
 32. Tremblay KD, Dunn NR, Robertson EJ. Mouse embryos lacking Smad1 signals display defects in extra-embryonic tissues and germ cell formation. *Development*. 2001;128(18):3609-3621.
 33. Wei CY, Wang HP, Zhu ZY, Sun YH. Transcriptional factors smad1 and smad9 act redundantly to mediate zebrafish ventral specification downstream of smad5. *J Biol Chem*. 2014;289(10):6604-6618.
 34. Shima DT, Kuroki M, Deutsch U, Ng YS, Adams AP, D'Amore PA. The mouse gene for vascular endothelial growth factor: genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. *J Biol Chem*. 1996;271(7):3877-3883.
 35. Kim RH, Wang D, Tsang M, et al. A novel smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-beta signal transduction. *Genes Dev*. 2000;14(13):1605-1616.
 36. Li W, Chen F, Nagarajan RP, Liu X, Chen Y. Characterization of the DNA-binding property of Smad5. *Biochem Biophys Res Commun*. 2001; 286(5):1163-1169.
 37. Henningfeld KA, Friedle H, Rastegar S, Knöchel W. Autoregulation of Xvent-2B; direct interaction and functional cooperation of Xvent-2 and Smad1. *J Biol Chem*. 2002;277(3):2097-2103.
 38. Park S, Lee YJ, Lee HJ, et al. B-cell translocation gene 2 (Btg2) regulates vertebral patterning by modulating bone morphogenetic protein/ smad signaling. *Mol Cell Biol*. 2004;24(23): 10256-10262.
 39. He C, Chen X. Transcription regulation of the vegf gene by the BMP/Smad pathway in the angioblast of zebrafish embryos. *Biochem Biophys Res Commun*. 2005;329(1):324-330.
 40. Postic C, Shiota M, Niswender KD, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. *J Biol Chem*. 1999;274(1):305-315.
 41. Umans L, Vermeire L, Francis A, Chang H, Huylebroeck D, Zwijsen A. Generation of a floxed allele of Smad5 for cre-mediated conditional knockout in the mouse. *Genesis*. 2003;37(1):5-11.
 42. Wang CY, Knutson MD. Hepatocyte divalent metal-ion transporter-1 is dispensable for hepatic iron accumulation and non-transferrin-bound iron uptake in mice. *Hepatology*. 2013;58(2):788-798.
 43. Canali S, Core AB, Zumbrennen-Bullough KB, et al. Activin B induces noncanonical SMAD1/5/8 signaling via BMP type I receptors in hepatocytes: evidence for a role in hepcidin induction by inflammation in male mice. *Endocrinology*. 2016; 157(3):1146-1162.
 44. Katakawa Y, Funaba M, Murakami M. Smad8/9 is regulated through the BMP pathway. *J Cell Biochem*. 2016;117(8):1788-1796.
 45. Nai A, Rubio A, Campanella A, et al. Limiting hepatic Bmp-Smad signaling by matrilipase-2 is required for erythropoietin-mediated hepcidin suppression in mice. *Blood*. 2016;127(19): 2327-2336.
 46. Tsukamoto S, Mizuta T, Fujimoto M, et al. Smad9 is a new type of transcriptional regulator in bone morphogenetic protein signaling. *Sci Rep*. 2014;4: 7596.
 47. Canali S, Vecchi C, Garuti C, Montosi G, Babitt JL, Pietrangelo A. The SMAD pathway is required for hepcidin response during endoplasmic reticulum stress. *Endocrinology*. 2016;157(10): 3935-3945.
 48. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. *Nat Med*. 2007;13(9):1096-1101.
 49. Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. *Blood*. 2009;114(1): 181-186.
 50. Tanno T, Rabel A, Lee YT, Yau YY, Leitman SF, Miller JL. Expression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donation. *Transfusion*. 2010;50(7):1532-1535.
 51. Theurl I, Finkenstedt A, Schroll A, et al. Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. *Br J Haematol*. 2010;148(3):449-455.
 52. Frazer DM, Wilkins SJ, Darshan D, Badrick AC, McLaren GD, Anderson GJ. Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression. *Br J Haematol*. 2012;157(5):615-626.
 53. Peng H, Truksa J, Lee P. EPO-mediated reduction in Hamp expression in vivo corrects iron deficiency anaemia in Tmprss6 deficiency. *Br J Haematol*. 2010;151(1):106-109.
 54. Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. *J Clin Invest*. 2010;120(12):4466-4477.
 55. Parrow NL, Gardenghi S, Ramos P, et al. Decreased hepcidin expression in murine beta-thalassemia is associated with suppression of Bmp/Smad signaling. *Blood*. 2012;119(13): 3187-3189.
 56. Aschemeyer S, Gabayan V, Ganz T, Nemeth E, Kautz L. Erythroferrone and matrilipase-2 independently regulate hepcidin expression. *Am J Hematol*. 2017;92(5):E61-E63.
 57. Broege A, Pham L, Jensen ED, et al. Bone morphogenetic proteins signal via SMAD and mitogen-activated protein (MAP) kinase pathways at distinct times during osteoclastogenesis. *J Biol Chem*. 2013;288(52):37230-37240.